Takeda may be paring back its R&D pipeline in the name of efficiency, but the Japanese pharma has still found $100 million to ensure its clinical pipeline once again features an Alzheimer’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results